Norvir

(Ritonavir)

ApprovedSmall molecule

Ritonavir is used to treat HIV infection by slowing the virus's ability to multiply in the body. It's often combined with other HIV medications to help keep the infection under control.[2] Norvir is currently approved and in use across 22 indications[4].[1]

Norvir is one of 536 small molecule programs targeting COVID-19. It is currently in Approved.

Indications

319

Total Trials

Active Trials

535

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

COVID-19Recruiting

Hepatitis C Virus InfectionActive, not recruiting

Viral DiseaseActive, not recruiting

Severe Acute Respiratory SyndromeActive, not recruiting

Kidney DiseaseApproved

Liver DiseaseApproved

Pulmonary Arterial HypertensionApproved

AIDSApproved

MetastasisApproved

Malignant GliomaApproved

COVID-19Phase 3

Recruiting

Hepatitis C Virus InfectionApproved

Active, not recruiting

Viral DiseaseApproved

Active, not recruiting

Severe Acute Respiratory SyndromePreclinical

Active, not recruiting

Kidney DiseaseApproved

Approved

Liver DiseaseApproved

Approved

Pulmonary Arterial HypertensionApproved

Approved

AIDSApproved

Approved

MetastasisApproved

Approved

Malignant GliomaApproved

Approved

Showing 10 of 22 indications

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Norvir

AbbVie

Approved

1 2

Zofran

Novartis

Preclinical

2 3

Nuvigil

NNuvo Research GmbH

Preclinical

1 4

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—7

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—8

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Systemic Therapy

1 10

JY231

SShenzhen Genocury Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Interaction18 trials

A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01519336·40 enrolled

Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00039975·32 enrolled

The Effects of Staggered Dosing on Interactions Between Paired Combinations of Nelfinavir, Ritonavir, and Saquinavir

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000898·18 enrolled

Show 15 more trials

Interactions of HIV Protease Inhibitors and Methadone in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000906·12 enrolled

The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02251119·24 enrolled

A Drug-Drug Interaction Study Between Danoprevir/Low-Dose Ritonavir and Cyclosporine in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01514968·18 enrolled

Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253901·33 enrolled

Pharmacokinetic Interaction Between Ritonavir and Prasugrel in Healthy Volunteers

Completed·UUniversity Hospital, Geneva·Phase 1·NCT01346800·10 enrolled

A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01591850·51 enrolled

GSK1349572 Drug Interaction Study With Atazanavir/Ritonavir and Atazanavir

Completed· GSK logo

GSK·Phase 1·NCT00883935·24 enrolled

A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs

Completed·RR-Pharm·Phase 1·NCT03537404·36 enrolled

Drug-Drug Interaction Study: ASP2151 and Ritonavir

Completed·MMaruho Europe Limited·Phase 1·NCT02223351·48 enrolled

TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 1·NCT01323257·49 enrolled

Drug-drug Interaction (DDI) Rifabutin

Completed· GSK logo

GSK·Phase 1·NCT02138084·102 enrolled

Drug-Drug Interaction Between Colchicine and Ritonavir

Completed·MMutual Pharmaceutical Company, Inc.·Phase 1·NCT00983515·24 enrolled

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

Completed· GSK logo

GSK·Phase 1·NCT01209065·27 enrolled

The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT01896622·40 enrolled

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin

Completed·UUniversity of Colorado, Denver·Phase 4·NCT00630734·32 enrolled

Tics13 trials

Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Completed·AAscletis Pharmaceuticals Co., Ltd.·Phase 1·NCT03288636·18 enrolled

Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02159352·49 enrolled

Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China

Completed·AAscletis Pharmaceuticals Co., Ltd.·Phase 1·NCT03019991·18 enrolled

Show 10 more trials

A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT01810887·8 enrolled

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of RO6889678 and the Combination of RO6889678 With Ritonavir in Healthy Participants

Terminated· Roche logo

Roche·Phase 1·NCT02321384·100 enrolled

A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT03593954·12 enrolled

Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500

Completed·VViriom·Phase 1·NCT02489487·24 enrolled

To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil

Completed·VVIVUS LLC·Phase 1·NCT00770042·44 enrolled

Pharmacokinetics of Tipranavir/Ritonavir and Its Metabolites in Healthy Male Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253797

The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT01148004·25 enrolled

To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01813552·24 enrolled

A Study to Evaluate The Effects of Two Different Meal Types, Omeprazole And Ranitidine On Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01392755·32 enrolled

Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02251769·24 enrolled

Effectiveness11 trials

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001075·55 enrolled

Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00004584

Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir

Terminated·AAgouron Pharmaceuticals·N/A·NCT00006326·60 enrolled

Show 8 more trials

Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Unknown status· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002451·8 enrolled

The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001087·300 enrolled

The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment

Unknown status· Merck & Co. logo

Merck & Co.·Phase 2·NCT00005118·100 enrolled

Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002361·30 enrolled

Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment

Unknown status· GSK logo

GSK·Phase 4·NCT00005017·300 enrolled

A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000914·800 enrolled

A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001108·6 enrolled

Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001091·200 enrolled

Chronic Hepatitis10 trials

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

Completed· Roche logo

Roche·Phase 2·NCT01278134·170 enrolled

A Study of Ritonavir-Boosted Danoprevir (RO5190591) in Combination With Pegasys and Ribavirin in Patients With Chronic Hepatitis C Genotype 1

Completed· Roche logo

Roche·Phase 1·NCT01185860·59 enrolled

ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment

Completed· Roche logo

Roche·Phase 2·NCT01628094·110 enrolled

Show 7 more trials

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Completed· AbbVie logo

AbbVie·Phase 2·NCT01306617·50 enrolled

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment

Withdrawn· Roche logo

Roche·Phase 2·NCT01579019

Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b

Completed·RR-Pharm·Phase 2·NCT03485846·105 enrolled

A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00797745·111 enrolled

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

Completed·AAscletis Pharmaceuticals Co., Ltd.·Phase 2/3·NCT03362814·425 enrolled

Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)

Completed·RR-Pharm·Phase 3·NCT03833362·420 enrolled

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

Completed· Roche logo

Roche·Phase 2·NCT01331850·381 enrolled

Treatment8 trials

A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients

Completed· Roche logo

Roche·Phase 3·NCT00002178·375 enrolled

A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients

Completed·TTibotec, Inc·Phase 2·NCT01199939·54 enrolled

A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug Treatment

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00006152·42 enrolled

Show 5 more trials

Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00056641·328 enrolled

Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00051831·19 enrolled

Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000940·121 enrolled

Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00530920·85 enrolled

A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients

Completed· Roche logo

Roche·Phase 1·NCT01638650·23 enrolled

66 more indications

Adult7 trials

Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

Completed·AAbbott·Phase 1·NCT00931281·38 enrolled

Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450

Completed·AAbbott·Phase 1·NCT01091649·40 enrolled

Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir

Completed·AAbbott·Phase 1·NCT00909311·8 enrolled

Show 4 more trials

Study to Determine the Effects of Multiple-dose Omeprazole on the Single-dose Pharmacokinetics of Tipranavir (TPV) Coadministered With Ritonavir (RTV) in Healthy Adult Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253875·15 enrolled

Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants

Completed· Pfizer logo

Pfizer·Phase 1·NCT05129475·12 enrolled

Dolutegravir and Darunavir Evaluation in Adults Failing Therapy

Unknown status·KKirby Institute·Phase 4·NCT03017872·831 enrolled

Effects of TPV/r on the Pharmacokinetics of Carbamazepine in Healthy Adult Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253849·28 enrolled

COVID-196 trials

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT05261139·160 enrolled

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT05047601·2,954 enrolled

A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19

Withdrawn· Pfizer logo

Pfizer·Phase 2·NCT05545319

Show 3 more trials

Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

Terminated· Pfizer logo

Pfizer·Phase 2/3·NCT05011513·1,440 enrolled

A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

Completed· Pfizer logo

Pfizer·Phase 2·NCT05567952·436 enrolled

EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT04960202·2,091 enrolled

HIV6 trials

A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients

Completed·AAbbott·N/A·NCT00002223

Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT00531206·65 enrolled

Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV Patients

Completed·GGermans Trias i Pujol Hospital·Phase 4·NCT00355719·14 enrolled

Show 3 more trials

A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients

Completed·AAbbott·N/A·NCT00002201

Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and Truvada

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00528060·35 enrolled

A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors

Completed·AAbbott·Phase 3·NCT00038636·36 enrolled

Children6 trials

A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000952·60 enrolled

Population Pharmacokinetics of Antiretroviral in Children

Completed·AAssistance Publique - Hôpitaux de Paris··NCT03194165·65 enrolled

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 2·NCT00919854·27 enrolled

Show 3 more trials

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001083·240 enrolled

A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000913·50 enrolled

A Study of Invirase (Saquinavir)/Ritonavir in HIV-Infected Infants and Children.

Completed· Roche logo

Roche·Phase 2·NCT00623597·18 enrolled

Efficacy and Safety6 trials

Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01620944·3 enrolled

Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

Completed· Gilead logo

Gilead·Phase 1/2·NCT01565889·52 enrolled

Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00421551·225 enrolled

Show 3 more trials

Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed·EEiger BioPharmaceuticals·Phase 3·NCT03719313·407 enrolled

A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.

Completed·HHarlan M Krumholz·Phase 2·NCT05668091·100 enrolled

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

Completed·AAscletis Pharmaceuticals Co., Ltd.·Phase 2·NCT03020004·70 enrolled

Immunodeficiency5 trials

Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02275780·769 enrolled

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Completed· Gilead logo

Gilead·Phase 3·NCT01106586·708 enrolled

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

Completed· GSK logo

GSK·Phase 3·NCT01910402·499 enrolled

Show 2 more trials

GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.

Completed·TTibotec, Inc·Phase 3·NCT00381303·429 enrolled

A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 2·NCT00355524·80 enrolled

HIV infection5 trials

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Completed·KKirby Institute·Phase 4·NCT00192660·80 enrolled

A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00006154·165 enrolled

Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT01691794·108 enrolled

Show 2 more trials

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000919·900 enrolled

A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.

Completed· Roche logo

Roche·Phase 1·NCT00435929·16 enrolled

Drug4 trials

A Study to Compare Two Anti-HIV Drug Combinations

Completed· Roche logo

Roche·Phase 3·NCT00002447·146 enrolled

A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 2·NCT00002440·80 enrolled

A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04055506·16 enrolled

Show 1 more trial

A Study to Compare Two Different Anti-HIV Drug Regimens

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000924·120 enrolled

TED4 trials

Single and Repeated Dose Escalation Study of GSK2838232

Completed· GSK logo

GSK·Phase 1·NCT02795754·62 enrolled

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Terminated· GSK logo

GSK·Phase 1·NCT02289495·24 enrolled

Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)

Completed·EEiger BioPharmaceuticals·Phase 2·NCT02430194·55 enrolled

Show 1 more trial

A Study of The Relative Bioavailability of Ritonavir-Boosted Danoprevir Fixed Dose Combination Tablets in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01592318·42 enrolled

Hepatitis C4 trials

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

Completed· AbbVie logo

AbbVie·Phase 2·NCT01464827·580 enrolled

Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

Completed· AbbVie logo

AbbVie·Phase 1·NCT00850044·87 enrolled

Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients

Completed· Novartis logo

Novartis·Phase 1/2·NCT01825980·54 enrolled

Show 1 more trial

A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT01724086·90 enrolled

Hepatic Impairment4 trials

Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332

Completed· Pfizer logo

Pfizer·Phase 1·NCT05005312·17 enrolled

A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment

Completed· Roche logo

Roche·Phase 1·NCT01185873·81 enrolled

A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls

Completed· Roche logo

Roche·Phase 1·NCT01714154·18 enrolled

Show 1 more trial

A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers

Completed·RR-Pharm·Phase 1·NCT03832426·32 enrolled

Single Dose3 trials

A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

Terminated· GSK logo

GSK·Phase 1·NCT02289482·20 enrolled

Pharmacokinetics of Single Doses of BILR 355 BS Given With Ritonavir in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253953·62 enrolled

Dose Escalation Study of Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BILR 355 (SDS) Plus Low-dose Ritonavir in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253927·48 enrolled

Adult Subject3 trials

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Completed·GGarden State Infectious Disease Associates, PA·Phase 2·NCT00764465·45 enrolled

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

Completed·GGarden State Infectious Disease Associates, PA·N/A·NCT00802074·45 enrolled

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Completed·GGarden State Infectious Disease Associates, PA·N/A·NCT00614991·44 enrolled

HIV-Infected Individuals3 trials

Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals

Terminated·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT02503462·7 enrolled

A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000859·1,300 enrolled

A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000822·46 enrolled

ART3 trials

Comparative Study of Three NNRTI-Sparing HAART Regimens

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 3·NCT00811954·1,814 enrolled

A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT04208061·28 enrolled

Food Effects of GST-HG171 Tablets Combined With Ritonavir in Healthy Chinese Participants

Unknown status·FFujian Akeylink Biotechnology Co., Ltd.·Phase 1·NCT06084507·18 enrolled

HIV-1 infection3 trials

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

Approved for marketing· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT00097799

GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection

Completed· Roche logo

Roche·Phase 3·NCT00105079·337 enrolled

A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT00976950·42 enrolled

Drug Resistance2 trials

Efficacy and Tolerability of an Antiretroviral Bi-Therapy in HIV Infected Patients With Multidrug Resistance

Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00120783·40 enrolled

Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug Resistance

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00046033·118 enrolled

Pilot Study2 trials

A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001688·25 enrolled

A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)

Completed· AbbVie logo

AbbVie·Phase 2·NCT01221298·11 enrolled

HIV-12 trials

A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients

Completed· Roche logo

Roche·Phase 3·NCT00002374·120 enrolled

A Study To Assess GW433908 (Fosamprenavir) Containing Regimens In HIV-1 Infected Subjects

Completed· GSK logo

GSK·Phase 3·NCT00296504·753 enrolled

MPR2 trials

Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR

Completed· GSK logo

GSK·Phase 3·NCT00043888·60 enrolled

Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir

Completed·RRadboud University Medical Center·Phase 1·NCT00817765·24 enrolled

Kaposi's sarcoma2 trials

Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003008·33 enrolled

The Safety and Effectiveness of Ritonavir in the Treatment of HIV-Related Kaposi's Sarcoma

Completed·AAbbott·Phase 2·NCT00002366

Tenofovir Disoproxil Fumarate2 trials

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 3·NCT00118898·1,864 enrolled

A Study of Drug-Drug Interaction Between Danoprevir Coadministered With Low-Dose Ritonavir and Tenofovir Disoproxil Fumarate or Atazanavir

Completed· Roche logo

Roche·Phase 1·NCT01592305·40 enrolled

Pediatric2 trials

A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years

Completed· GSK logo

GSK·Phase 2·NCT00040664·69 enrolled

Study Of An Investigational Regimen Including FDA Approved HIV Drugs In HIV-Infected Pediatric Subjects

Completed· GSK logo

GSK·Phase 2·NCT00071760·59 enrolled

Drug Interactions2 trials

Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00005762·90 enrolled

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00833482·185 enrolled

Hepatitis2 trials

Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT02511431·22 enrolled

Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT03600714·26 enrolled

Female2 trials

Bioequivalence Study of Tipranavir Stored at Controlled Temperature Compared With Tipranavir Stored at Controlled Refrigerated Conditions, Orally Co-administered With Ritonavir in Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253888·30 enrolled

Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01374802·14 enrolled

Adolescent2 trials

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00006604·195 enrolled

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 2·NCT00915655·12 enrolled

HBV1 trial

Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00447902·11 enrolled

Pregnancy1 trial

Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000920·24 enrolled

Advanced Breast Cancer1 trial

Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT06710990·32 enrolled

Second-line Treatment1 trial

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01605084

Phase II1 trial

Phase IIB Pilot of Atazanavir + Raltegravir

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00768989·167 enrolled

Viremia1 trial

HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 4·NCT00855413·15 enrolled

Menstrual Cycle1 trial

Impact of Menstrual Cycle on Antiretroviral Pharmacokinetics in Healthy Women

Completed·UUniversity of Alabama at Birmingham·Phase 4·NCT00869960·24 enrolled

Impaired Renal Function1 trial

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT02116660·11 enrolled

Combination Therapy1 trial

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01448707·274 enrolled

Hepatitis D Virus Infection1 trial

Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection

Unknown status·SSoroka University Medical Center·Phase 3·NCT05229991·30 enrolled

Mycobacterium Avium Complex1 trial

A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001058·246 enrolled

Statin1 trial

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz

Completed·NNYU Langone Health·Phase 1·NCT01695954·34 enrolled

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02245269·23 enrolled

Breast Cancer1 trial

Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT01009437·28 enrolled

Methadone1 trial

Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02245451·15 enrolled

Glioma1 trial

Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma

Terminated·—·Phase 2·NCT01095094·19 enrolled

Hepatitis B1 trial

Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02259855·36 enrolled

Tolerance1 trial

Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001133·50 enrolled

Antiretroviral Treatment1 trial

Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive

Withdrawn·JJuan A. Arnaiz·Phase 4·NCT02470650

Radiation Therapy1 trial

External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases

Unknown status·OOncology Institute of Southern Switzerland·Phase 2·NCT00637637·60 enrolled

Drug Therapy1 trial

A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000902·217 enrolled

CLE1 trial

Nucleosides And Darunavir/Dolutegravir In Africa

Unknown status·MMakerere University·Phase 3·NCT03988452·465 enrolled

Tuberculosis1 trial

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)··NCT04518228·205 enrolled

Platelet Function1 trial

Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02251795·52 enrolled

Treatment Failure1 trial

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000918·300 enrolled

Progesterone1 trial

Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00016601·76 enrolled

Maintenance Therapy1 trial

Atazanavir/Ritonavir Maintenance Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00084019·36 enrolled

MPA1 trial

Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02259868·88 enrolled

Amyotrophic Lateral Sclerosis1 trial

HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT02437110·122 enrolled

Pregnant Women1 trial

Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000888·14 enrolled

Bone1 trial

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT01400412·262 enrolled

Randomized1 trial

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

Terminated· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00440271·33 enrolled

Cardiovascular1 trial

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections··NCT00851799·334 enrolled

Function1 trial

Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function

Completed· GSK logo

GSK·Phase 4·NCT00717067·30 enrolled

Oral1 trial

Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02244190·32 enrolled

Prostate Cancer1 trial

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

Terminated·UUniversity of Chicago·Phase 1·NCT05679388·60 enrolled

Unspecified8 trials

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

Completed· GSK logo

GSK·Phase 3·NCT00085943·866 enrolled

Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02253862·17 enrolled

A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers

Completed·PPyramid Biosciences·Phase 1·NCT05692570·21 enrolled

Show 5 more trials

A Relative Bioavailability Study of Danoprevir and Ritonavir in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01483729·36 enrolled

Relative Bioavailability of a Single-dose Administration of BIBW 2992 and Multiple-dose Administration of Ritonavir in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02171754·22 enrolled

A Study of Danoprevir in Combination With Low-Dose Ritonavir in Healthy Subjects

Completed· Roche logo

Roche·Phase 1·NCT01398293·52 enrolled

A Study of RO5190591 (Danoprevir) in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT01164488·18 enrolled

Lonafarnib With and Without Ritonavir in HDV (LOWR-1)

Completed·EEiger BioPharmaceuticals·Phase 2·NCT02430181·21 enrolled

Regulatory

FDA Approval Timeline[5]

Mar 1, 1996

NORVIR

NDA NDA020680

Mar 1, 1996

NORVIR

NDA NDA020659

Jun 29, 1999

NORVIR

NDA NDA020945

Feb 10, 2010

NORVIR

NDA NDA022417

Jun 7, 2017

NORVIR

NDA NDA209512

Sources

References

[1]
ClinicalTrials.gov — 319 trial records for Ritonavir. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Norvir drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Ritonavir compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Ritonavir. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA209512). U.S. Food & Drug Administration.
[6]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Cytochrome P450 3a Inhibitor; Human Immunodeficiency Virus Type 1 Protease Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AbbVie

Norvir

Status by Indication[4][1]

Competitive Landscape

Trials by Indication[1]

Interaction18 trials

Tics13 trials

Effectiveness11 trials

Chronic Hepatitis10 trials

Treatment8 trials

Adult7 trials

COVID-196 trials

HIV6 trials

Children6 trials

Efficacy and Safety6 trials

Immunodeficiency5 trials

HIV infection5 trials

Drug4 trials

TED4 trials

Hepatitis C4 trials

Hepatic Impairment4 trials

Single Dose3 trials

Adult Subject3 trials

HIV-Infected Individuals3 trials

ART3 trials

HIV-1 infection3 trials

Drug Resistance2 trials

Pilot Study2 trials

HIV-12 trials

MPR2 trials

Kaposi's sarcoma2 trials

Tenofovir Disoproxil Fumarate2 trials

Pediatric2 trials

Drug Interactions2 trials

Hepatitis2 trials

Female2 trials

Adolescent2 trials

HBV1 trial

Pregnancy1 trial

Advanced Breast Cancer1 trial

Second-line Treatment1 trial

Phase II1 trial

Viremia1 trial

Menstrual Cycle1 trial

Impaired Renal Function1 trial

Combination Therapy1 trial

Hepatitis D Virus Infection1 trial

Mycobacterium Avium Complex1 trial

Statin1 trial

Tenofovir1 trial

Advanced1 trial

Atorvastatin1 trial

Breast Cancer1 trial

Methadone1 trial

Glioma1 trial

Hepatitis B1 trial

Tolerance1 trial

Antiretroviral Treatment1 trial

Radiation Therapy1 trial

Drug Therapy1 trial

CLE1 trial

Tuberculosis1 trial

Platelet Function1 trial

Treatment Failure1 trial

Progesterone1 trial

Maintenance Therapy1 trial

MPA1 trial

Amyotrophic Lateral Sclerosis1 trial

Pregnant Women1 trial

Bone1 trial

Randomized1 trial

Cardiovascular1 trial

Function1 trial

Oral1 trial

Prostate Cancer1 trial

Unspecified8 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News